Isoplexis and Nektar Therapeutics collaborate to further analyze NKTR-214
On June 26, Isoplexis, a privately held life sciences company, and Nektar Therapeutics, announced a collaboration focused on the functional impact of Nektar’s NKTR-214 in the clinical setting at the single-cell level with the aim to reveal the mechanism and potential immune correlation with the outcome. The collaboration aims to employ Isoplexis’s IsoCode Chip’s single-cell functional profiling for profiling the effects of Nektar’s NKTR-214 drug in both monotherapy and combination treatments in a clinical setting.
In a recent study, the preclinical data captured by Isoplexis’s IsoCode Chip showed that Nektar Therapeutics’ NKTR-214 “can significantly boost the activation of critical T cell subsets, termed polyfunctional T cells, in combination with adoptive cell transfer (ACT) therapies.”
IsoPlexis’s chief executive officer, Sean Mackay, said, “We are excited to collaborate with Nektar Therapeutics and further demonstrate the broad impact of NKTR-214 and its ability to induce critical T cell responses in cancer immunotherapy. We recently released pre-clinical data highlighting the ability of NKTR-214 to activate key subsets of highly functional immune cells, and look forward to further profile the therapy’s immune-based mechanisms and correlates in the clinic.”
According to Jon Zalevsky, Nektar’s chief scientific officer, “We see potential in utilizing IsoPlexis’s single-cell system to help provide deeper resolution into the functional impacts of our therapeutics. This collaboration will enable us to apply the sensitivity of this solution to further our understanding of patient-specific responses to our immune therapies.”
Check out all the data we’ve added to our quote pages. Now you can get a valuation snapshot, earnings and revenue estimates, and historical data as well as dividend info. Take a look!